S112 Optimal Timing and Donor-Patient Matching of Fecal Microbiota Transplantation for Ulcerative Colitis

tologic remission. Methods: To determine the prevalence of patients with idiopathic chronic ulcerative colitis who achieve deep remission in a tertiary care center, a search was made in the internal electronic system of active patients cataloged with the pathology of ulcerative colitis. Results: Forty-seven patients were included, of which 48% were female. The main treatment they were receiving was Infliximab 20%, Adalimumab 22%, Certolizumab 18%, Vedolizumab 4% and Ustekinumab 2%, 5-aminosalicylic acid (5-ASA) 20%. Thirty-eight percent of patients were in clinical remission, followed by biochemical remission in 30%, 17% in endoscopic remission, and 7% in deep remission. Conclusion(s): Within our study, it was found that patients who were in profound and clinical remission were maintained under a regimen with adalimumab. Our percentage of deep remission was lower than that reported since many patients were in both clinical and biochemical remission, but due to the saturation of endoscopy services, we had to opt to postpone the study.